Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies
Portfolio Pulse from Benzinga Newsdesk
Grifols's subsidiary Biotest forecasts approximately $1 billion in revenue from U.S. sales of its FDA-approved intravenous immunoglobulin Yimmugo over the next seven years. Yimmugo will launch in Q1 2025 and be distributed by Kedrion. This adds to Grifols' strong portfolio of immunoglobulins.
July 01, 2024 | 10:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Grifols's subsidiary Biotest expects $1 billion in revenue from U.S. sales of its FDA-approved intravenous immunoglobulin Yimmugo over the next seven years. The product will launch in Q1 2025 and be distributed by Kedrion, adding to Grifols' strong portfolio of immunoglobulins.
The FDA approval and expected revenue from Yimmugo significantly enhance Grifols' portfolio and market position in the U.S. immunoglobulin market. The launch and distribution strategy indicate strong future revenue streams.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100